USA flag logo/image

An Official Website of the United States Government

The First Locally Acting Anti-Inflammatory Stem Cell-Based Therapy for…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
Program Year/Program:
2012 / SBIR
Agency Tracking Number:
R43AR061902
Solicitation Year:
2012
Solicitation Topic Code:
NIAMS
Solicitation Number:
PA10-122
Small Business Information
WIBI WORKS, LLC
5230 COLISEUM ST NEW ORLEANS, LA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2012
Title: The First Locally Acting Anti-Inflammatory Stem Cell-Based Therapy for Rheumatoid
Agency: HHS
Contract: 1R43AR061902-01A1
Award Amount: $400,000.00
 

Abstract:

DESCRIPTION (provided by applicant): The First Locally Acting Anti-Inflammatory Stem Cell-Based Therapy for Rheumatoid Arthritis Despite improved therapy; rheumatoid arthritis (RA) remains a significant unmet medical need. The long-term goal of this project is to advance the first stem cell-based product for anti-inflammatory therapy of RA. Many ongoing or completed clinical trials have established that mesenchymal stem cell (MSC)-based therapies are safe and effective in the treatment of human diseases. MSCs used in these therapies are derived from various adult human tissues, naturally home to inflamed sites, and help to repair these sites by establishing a local anti-inflammatory microenvironment. Extensive research has shown that MSCs from one human do not cause an immune response in another, nor is an immune response elicited in animals injected with human MSCs. As a result, many new and existing businesses are developing off-the-shelf allogeneic (non-self) MSC-based products for the treatment of a wide-ranging set of human diseases. However, one major drawback is that the current methods to prepare MSCs yield a mixed, poorly defined pool of cells that make the therapeutic out- comes inconsistent and difficult to predict. We have developed a new technology that renders MSC preparations more uniform by inducing them into a discrete anti-inflammatory phenotype (MSC2). Wibi+Works, LLC intends to market MSC2 as an off-the-shelf product for the targeted treatment of human inflammatory diseases. [Our central hypothesis for this study is that MSC2-based therapy is consistently safe and effective in the local anti-inflammatory treatment of rheumatoid arthritis. MSC2 are expected to home to inflamed sites and through their secretion of soluble factors and cell-cellcontact with inflammatory cells to shit the affected tissue milieu toward homeostasis and repair. The overall goal of this Phase I study is to generate proof of principle data validating MSC2 as a consistently local anti-inflammatory therapy that safely improves disease outcomes in an established murine collagen induced arthritis model. Further, by specifically acting at the affected site many of the adverse effects seen with conventional systemic anti-inflammatory treatments will be avoided by this cell-based therapy. The aims we propose in pursuit of this goal are: 1. Determine the efficacy of MSC2 over conventional MSC treatment in murine collagen-induced arthritis (CIA), and 2. Determine the mechanisms behind decreased arthritis severity in MSC2-treated CIA mice.] In the follow-up Phase II study, it is expected that a clinical grade MSC2 product (wibi+cells) will be expanded, banked and tested for safety, efficacy, tumorigenicity, and toxicity in anticipation of filing withthe FDA to designate wibi+cells as an investigational new drug (IND) to test in pilot clinical trials o RA. This Phase I study represents the initial step for Wibi+Works, LLC in its goal of producing the first anti-inflammatory MSC2-based therapy of rheumatoid arthritis in the US andthat stands alone as a local, not systemic, treatment with the potential to promote the repair of affected joints. PUBLIC HEALTH RELEVANCE: Public Health Relevance: Millions of Americans suffer from rheumatoid arthritis (RA) every year. It is a debilitating disease associated with progressive join destruction, functional disability, and decreased life expectancy. This study aims to advance the first anti-inflammatory mesenchymal stem cell (MSC)-based product for the treatment of rheumatoid arthritis. Unlike any of the currently available anti-inflammatory medications, MSCs used in this therapy are anticipated to go to the affected sites, to directly treat the inflammatio, and to promote repair of the affected joints. By going to work directly at the inflamed tissues it s expected that the adverse effects of conventional anti-inflammatory medications will be avoided. The new technology used in the preparation of the MSC-product (MSC2) being tested here overcomes the major obstacle of current MSC-based therapy by ensuring a consistently effective and reproducible anti-inflammatory MSC phenotype.

Principal Investigator:

Aline Betancourt
504-988-1934
wibi.works.now@gmail.com

Business Contact:

Aline Betancourt
504-427-1450
wibi.works.now@gmail.com
Small Business Information at Submission:

WIBI WORKS, LLC
5230 COLISEUM ST NEW ORLEANS, LA -

EIN/Tax ID: 127330008
DUNS: N/A
Number of Employees: N/A
Woman-Owned: Yes
Minority-Owned: No
HUBZone-Owned: No